In a randomized, double-blind, placebo-controlled trial, 150 participants with knee osteoarthritis were allocated to either placebo, approximately 187 mg of a turmeric rhizome extract, or 280 mg daily for 3 months.
74 participants completed the entire trial, while 141 were able to be included in the intention to treat analysis. At the end of 3 months, both curcumin groups saw a statistically significantly greater improvement in Patients Global Assessment of Disease Activity score than placebo, and there were no statistically significant differences between them. Markers of collagen breakdown were reduced significantly in the curcumin groups but not the placebo group. Pain on the visual analog scale was significantly improved compared with placebo in both curcumin groups, with no notable differences between them. Symptoms on the Knee injury and Osteoarthritis Outcome Score were improved more in the curcumin groups, with the greatest improvement in the high-dose group, but there were no statistically significant differences between groups.
Funding issues for this study:
"All the operational phase of this study (patient recruitment, data collection, and statistical analysis) was funded by Tilman SA."